<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00871234</url>
  </required_header>
  <id_info>
    <org_study_id>0812-18 (TMC125HIV4003)</org_study_id>
    <nct_id>NCT00871234</nct_id>
  </id_info>
  <brief_title>Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study</brief_title>
  <official_title>Effects of Etravirine (INTELENCETM) on Endothelial Function in HIV-uninfected Adults: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effects of etravirine, an HIV
      antiretroviral medication, on vascular function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that in HIV-uninfected subjects, etravirine 200mg twice daily for four weeks
      will have no effect on endothelial function. The primary objective of this study is to
      determine the effects of etravirine 200mg twice daily given for four weeks on endothelial
      function, measured as flow-mediated dilation (FMD) of the brachial artery, in HIV-uninfected
      subjects. Secondary objectives include determination of the effects of etravirine 200mg twice
      daily given for four weeks on safety measures, lipid fractions, HOMA-IR, blood pressure,
      inflammatory parameters, and endothelial activation parameters.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow-mediated Dilation (FMD) of the Brachial Artery</measure>
    <time_frame>Entry and four weeks</time_frame>
    <description>FMD is measured as the percentage increase in brachial artery diameter after increase in blood flow. We measured the change in this percentage from entry (before etravirine was started) and again at four weeks after receiving etravirine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid Fractions</measure>
    <time_frame>Four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity [(Homeostasis Model Assessment-Insulin Resistance (HOMA-IR)]</measure>
    <time_frame>Four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Biomarkers</measure>
    <time_frame>Four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial Activation Biomarkers</measure>
    <time_frame>Four weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">28</enrollment>
  <condition>Endothelial Function</condition>
  <condition>Lipids</condition>
  <condition>Insulin Resistance</condition>
  <condition>Inflammation</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etravirine</intervention_name>
    <description>Two one-hundred mg tablets orally twice daily for four weeks</description>
    <other_name>INTELENCETM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older

          2. Negative ELISA for HIV-1 or HIV-2 at screening

          3. Negative hepatitis B surface antigen at screening

          4. Negative hepatitis C antibody at screening

          5. For women of reproductive potential, a negative urine pregnancy test at screening and
             willingness to use two forms of birth control during the course of the study

          6. No history of diabetes, hypertension, or dyslipidemia

          7. No anticipated changes or additions to other medical therapies during the course of
             the study

        Exclusion Criteria:

          1. Inability to provide written, informed consent

          2. Known allergy/intolerance to etravirine or nitroglycerin

          3. Absolute neutrophil count &lt; 750cell/mL at screening

          4. Hemoglobin &lt;11g/dL at screening

          5. Platelet count &lt;100,000/mL at screening

          6. Estimated creatinine clearance (per Cockcroft-Gault equation) &lt;55 mL/min at screening

          7. Liver transaminases (AST or ALT) &gt; 100 IU/mL or total bilirubin &gt; 1.5mg/dL at
             screening

          8. Breastfeeding at screening and during the course of the study

          9. Hypotension, defined as SBP&lt;90mmHg at time of each main study visit before brachial
             artery ultrasound measurements

         10. Receipt of investigational agents, cytotoxic chemotherapy, systemic glucocorticoids
             (&gt;10mg/day of prednisone or the equivalent), or anabolic steroids within 30 days of
             each screening visit or each main study visit

         11. Use of sildenafil (Viagra or Silagra), vardenafil (Levitra), or tadalafil (Cialis),
             within 72 hours (before or after) of brachial artery reactivity testing

         12. Indwelling vascular catheters within any upper body vessel at time of brachial artery
             reactivity testing

         13. Active drug or alcohol use or dependence that, in the opinion of the investigator,
             would interfere with adherence to study requirements

         14. Acute therapy for serious infection or other serious medical illnesses (in the
             judgment of the site investigator) requiring systemic treatment and/or hospitalization
             within 14 days prior to each screening and study visit

         15. History of migraine headaches

         16. History of Raynaud's phenomenon

         17. History of cardiac arrythmias

         18. History of hypothyroidism or hyperthyroidism that is untreated (defined as a TSH
             outside the normal range on most recent testing during normal clinical care)

         19. History of carotid bruits.

         20. History of any tobacco use (cigarette smoking, cigar smoking, chewing tobacco) or
             nicotine replacement treatments (patch, gum) within one year of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir K Gupta, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Infectious Diseases Research Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2009</study_first_submitted>
  <study_first_submitted_qc>March 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2009</study_first_posted>
  <results_first_submitted>December 7, 2010</results_first_submitted>
  <results_first_submitted_qc>December 7, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 5, 2011</results_first_posted>
  <last_update_submitted>January 5, 2011</last_update_submitted>
  <last_update_submitted_qc>January 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Samir K. Gupta, MD, MS</name_title>
    <organization>Indiana University School of Medicine</organization>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Endothelial function</keyword>
  <keyword>Etravirine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etravirine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred between April 2009 and March 2010. Participants were recruited via advertisements and word-of-mouth.</recruitment_details>
      <pre_assignment_details>After participant enrollment, a screening visit was performed to determine eligibility. Participants may have been excluded from entering the study if they were found to be ineligible.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Etravirine</title>
          <description>Healthy volunteers receiving etravirine 200mg orally twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Etravirine</title>
          <description>Healthy volunteers receiving etravirine 200mg orally twice daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" lower_limit="28" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Flow-mediated Dilation (FMD) of the Brachial Artery</title>
        <description>FMD is measured as the percentage increase in brachial artery diameter after increase in blood flow. We measured the change in this percentage from entry (before etravirine was started) and again at four weeks after receiving etravirine.</description>
        <time_frame>Entry and four weeks</time_frame>
        <population>FMD analysis was per protocol restricted to those who completed the four week trial. The safety analysis was ITT.</population>
        <group_list>
          <group group_id="O1">
            <title>Etravirine</title>
            <description>Healthy volunteers receiving etravirine 200mg orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Flow-mediated Dilation (FMD) of the Brachial Artery</title>
          <description>FMD is measured as the percentage increase in brachial artery diameter after increase in blood flow. We measured the change in this percentage from entry (before etravirine was started) and again at four weeks after receiving etravirine.</description>
          <population>FMD analysis was per protocol restricted to those who completed the four week trial. The safety analysis was ITT.</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="-3.21" upper_limit="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Wilcoxon signed-rank</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipid Fractions</title>
        <time_frame>Four weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Sensitivity [(Homeostasis Model Assessment-Insulin Resistance (HOMA-IR)]</title>
        <time_frame>Four weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure</title>
        <time_frame>Four weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Biomarkers</title>
        <time_frame>Four weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endothelial Activation Biomarkers</title>
        <time_frame>Four weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Six weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Etravirine</title>
          <description>Healthy volunteers receiving etravirine 200mg orally twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Both Grade 1; both resolved spontaneously within 11 days and were not treatment limiting.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <description>Both Grade 1; both resolved spontaneously within 2 days and were not treatment limiting.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>All Grade 1; all resolved spontaneously within 11 days and were not treatment limiting.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathic tingling or pain</sub_title>
                <description>Both Grade 1; both resolved spontaneously within 3 days and were not treatment limiting.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>All Grade 1; all spontaneously resolved within 12 days and were not treatment-limiting.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Both Grade 1; both resolved spontaneously within 2 days and were not treatment limiting.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Both Grade 2; both resolved within 3 days upon discontinuation of study drug.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Samir K. Gupta, MD, MS</name_or_title>
      <organization>Indiana University School of Medicine</organization>
      <phone>317-274-7926</phone>
      <email>sgupta1@iupui.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

